COVID-19: Keep up to date with the latest pharmaceutical and healthcare news as the pandemic evolves

The Pharma Fast 50

PharmaTimes presents Alantra’s annual ranking of the fastest growing private pharma companies in the UK
Powerful progress

Veeva’s predictions for the life sciences industry in 2021
Cash controllers

Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs

News

View all

FDA to review Sanofi’s Dupixent in children with uncontrolled asthma

Sanofi is also planning an EU regulatory submission for Dupixent in the same indication

5th March 2021

Lilly’s tirzepatide claims head-to-head trial win against injectable semaglutide

Tirzepatide demonstrated superior A1C and body weight reduction in type 2 diabetes

5th March 2021

ClinSpec Diagnostics reaches funding target of £3.5m

University of Strathclyde spin-out is developing liquid biopsies for early cancer detection

5th March 2021

Modified COVID-19 vaccines can avoid ‘lengthy’ clinical studies, says MHRA

UK’s regulatory authority will fast-track jabs modified to new variants

5th March 2021

ConserV Bio partners with eTheRNA on mRNA vaccine development

Collaboration will focus on vaccines for infectious diseases

4th March 2021

Web Exclusives

View all

The Immigration Exemption and the GDPR

Will the UK government’s controversial immigration exemption will be removed from the Data Protection Act? Here's why it matters

Creating visible and valuable vaccine content

How pharma companies can create digital content that satisfies demand and meets Google’s specific criteria for keeping users safe

A new focus

Castleman disease (CD) is a rare and potentially life-threatening disease. Like so many rare diseases, it is often misdiagnosed, or goes undiagnosed. On Rare Disease Day, EUSA Pharma’s Jon Morgan, VP global head of Medical, discusses the need to bring a new focus to rare diseases like CD

A call to action

If we want to beat COVID-19, vaccination must be an urgent global effort

Magazine

View more from the latest edition

Time for change

Why governments need to rethink their regulatory framework in 2021

Smart People: Andrew Meade

PharmaTimes talks to Andrew Meade, Accenture’s UK and Ireland Life Sciences lead, about the opportunities and challenges triggered by COVID-19 for medicine and digital tech

In sickness and in health

Exploring the relationship between the microbiome, precision medicine and cancer

The missing piece of the puzzle

Supplementing disease modelling with microbiome data is set to enable the life sciences industry to understand more about how drugs interact with different people, and devise more targeted treatments. Anthony Finbow explains how the science of microbiomes will increasingly contribute to pharma research outcomes

Hidden impact

The effect of the COVID-19 pandemic on lung cancer care, and learning lessons from across Europe

A global effort?

COVID-19 threw pharma’s performance on access to medicine into the spotlight. Has the industry passed the test?

Cash controllers

Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs